Oxaliplatin Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-170

This is a medical study evaluating the probability of DFS (disease-free survival) for two treatment arms, FOLFOX4 and WSFU2. The graph shows Kaplan-Meier curves over a period of 72 months for both arms. The Hazard Ratio for FOLFOX4 vs WSFU2 is 0.8 with a 95% CI of [0.68,0.93]. The Stratified Logrank Test resulted in p-value 0.003. The legend provides information on the number of events for each arm at respective time intervals.*

This is a statistical analysis of DFS (disease-free survival) probability for two treatment arms named FOLFOX4 and LVSFUZ - each in Dukes G stage ll patients. The analysis is based on Kaplan-Meier curves and hazard ratios. The notation and abbreviations may be difficult for non-experts to understand.*

The text refers to a study on the median survival of patients who received Oxaiplatin for Injection plus 5-FULV, Oxaiplatin for Infection plus rnotezan, or irinotecan plus 5-FULY. The survival rates are shown as percentages at different time intervals (0, 3, 9, 12, 15, 13, 21, and 24 months), and the results were analyzed using the log rank test. Additionally, a Kaplan-Meier plot shows the overall survival by treatment arm in months. It is impossible to know the complete context and conclusions of the study based on this text alone.*

This is a medication with NDC code 68083-170-01 that is only available through prescription. Each vial of the medication contains 50mg of Oxallplatin Xaliplatin USP and 450mg of Lactose Monohydrate NF. It is a cytotoxic agent that must be stored at the temperature range of 20° to 25°C (68° to 77°F), with excursions between 15° to 30°C (59° to 86°F). The medication must be reconstituted and diluted before use. The package insert contains instructions for dosage, reconstitution, and further dilution. The medication is manufactured by Gland Pharma Limited, and the code number is APDRUCSI02201. The unused portion must be discarded, and the package insert contains information on storage for the reconstituted and diluted solutions. Do not reconstitute with sodium chloride/chloride-containing solutions.*

Oxaliplatin for Injection is a cytotoxic agent available in single-dose vials that contain preservative-free, sterile lyophilized powder. The drug must be reconstituted and diluted before intravenous use only. The vial contains 50 mg of the active ingredient Oxaliplatin USP and 450 g of lactose monohydrate NF that is mixed with either 10 mL of Water for Injection, USP, or 5% Dextrose Injection, USP. The drug must not be reconstituted with solutions containing sodium chloride/chloride. The package includes dosage and administration instructions and guidelines for reconstitution and further dilution before intravenous administration. The medicine is produced by Gland Pharma Limited in Visakhapatnam, India. Lot and Exp details are provided.*

Oxaliplatin for Injection is a cytotoxic agent used intravenously for single-use vial with sterile lyophilized powder (preservative-free) to be reconstituted and diluted before use. This drug is not supposed to be reconstituted with sodium chloride/chloride-containing solutions. Each vial contains 100mg Oxaliplatin USP and 900mg Lactose Monohydrate NF as inactive ingredients, and no preservative. Usual dosage and packaging details can be found in the package insert. The drug must be stored at a temperature of 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The unused portion must be discarded, and the remaining information is available in the package insert. The manufacturer is Gland Pharma Limited, Visakhapatnam, India.*

Oxaliplatin is a cytotoxic agent provided in a sterile lyophilized powder form without preservatives. It is to be reconstituted and diluted before intravenous administration. The vial contains oxaliplatin USP in the quantity of 100mg with Lactose Monohydrate NF 900g as an inactive ingredient. Reconstitution instructions are given in the package insert, and the unused portion should be discarded as per the instructions. Oxaliplatin must not be reconstituted using Chloride-containing Solutions or Sodium Chloride. Manufacturing is done by Gland Pharma Limited, located in Visakhapatnam, India. The page also contains codes and NDC numbers.*